Trial Profile
The Use of Tocilizumab in the Management of Patients Who Have Severe COVID-19 With Suspected Pulmonary Hyperinflammation
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 03 Aug 2022
Price :
$35
*
At a glance
- Drugs Tocilizumab (Primary)
- Indications Adult respiratory distress syndrome; COVID-19 pneumonia; Hypoxia
- Focus Therapeutic Use
- 08 May 2020 New trial record